2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1479 PU.1 inhibition sensitizes stem-monocytic acute myeloid leukemia to BCL2 blockade

Itallia Pacentine, PhD, MSc, William M Yashar, MD PhD2, Akram Taherinasab, PhD3, Thai Nguyen, MS4, Samantha Worme, MS5, Mitsuhiro Tsuchiya, MS6, Scott Streitfeld, PhD7, Theresa Lusardi, PhD8, Chelsea Hutchinson9, Thomas Fillmore10, Camilo Posso11, Sara J Gosline12, Paul Piehowski13, Shawn Shrestha14, Wei Xie15, Phillipp Raess, MD, PhD16, Galip Gurkan Yardimci, PhD17, Andrew Adey, PhD18, Julia Maxson, PhD19, Theodore Paul Braun, MD PhD20
1 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
2 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
3 Oregon Health Sciences University, Portland, Oregon, United States
4 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
5 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
6 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
7 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
8 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
9 Pacific Northwest National Laboratory, Seattle, Washington, United States
10 Pacific Northwest National Laboratory, Seattle, Washington, United States
11 Pacific Northwest National Laboratory, Seattle, Washington, United States
12 Pacific Northwest National Laboratory, Seattle, Washington, United States
13 Pacific Northwest National Laboratory, Seattle, Washington, United States
14 Oregon Health Sciences University, Portland, Oregon, United States
15 Oregon Health Sciences University, Portland, Oregon, United States
16 Oregon Health Sciences University, Portland, Oregon, United States
17 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
18 Oregon Health Sciences University, Portland, Oregon, United States
19 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States
20 OHSU Knight Cancer Institute, Portland, Oregon, United States, Oregon Health & Science University, Portland, Oregon, United States, Oregon Health Sciences University, Portland, Oregon, United States

Acute myeloid leukemia (AML) exhibits substantial transcriptional heterogeneity across differentiation states that influences therapeutic response to BCL2 inhibition with venetoclax. While hematopoietic stem cell (HSC)-like AMLs are acutely sensitive to venetoclax and monocytic-like AMLs demonstrate resistance, the therapeutic behavior of leukemias harboring both transcriptional programs remains poorly defined. Analysis of a large AML cohort reveals a distinct patient population exhibiting concurrent HSC- and monocyte-like transcriptional signatures, which we term stem-monocytic AML. Ex vivo drug sensitivity profiling demonstrates that stem-monocytic AMLs exhibit venetoclax resistance comparable to purely monocytic-like AML, despite expressing HSC-like transcriptional features. Using a leukemia cell line, OCI-AML8227, that recapitulates the differentiation spectrum of stem-monocytic AML, we show through immunophenotyping and single-cell lineage tracing that venetoclax preferentially depletes stem-like AML cells while sparing monocytic-like AML cells. Single-cell transcriptomic and chromatin accessibility analyses identify enrichment of myeloid differentiation transcription factors, particularly PU.1, in resistant populations. A targeted CRISPR knockout screen confirms that PU.1 disruption induces differentiation arrest and enhances venetoclax sensitivity in immature immunophenotypic compartments. Pharmacologic PU.1 inhibition with the small molecule DB2313 enhances the efficacy of venetoclax in both cell line models and primary stem-monocytic AML patient samples. These findings establish stem-monocytic AML as a transcriptionally and functionally distinct subtype and nominate combined BCL2 and PU.1 inhibition as a rational therapeutic strategy for improving venetoclax response in this patient population.

Itallia Pacentine, PhD, MSc: No relevant conflicts of interest to declare.